Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 85.73

-2.8%

Jan 23 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (2650)	2/2/2010 2:23:23 PM
From: Jibacoa	Read Replies (1) of 3722

ACHN was up 18.59% at its intraday H at 11:54AM and 12:04PM It is still up 12.81% in spite of that intraday double top, with the help of some upticks as I am writting this note.<g> The stock traded above its Jan19 H, and it already has closed its Dec16 UG. Volume of > 2,394,700 is almost 4x its ADV bigcharts.marketwatch.com It announced that it has entered a partnership to develop and sell its hepatitis B and HIV drug candidate elvucitabine in China and other territories. Yesterday it announced a marketing partnership with GCA Therapeutics. The terms were not disclosed, but the companies said GCA will have the right to develop and sell elvucitabine in China, Hong Kong, and Taiwan through a joint venture with Tianjing Institute of Pharmaceutical Research. ACHN could receive milestone payments if the drug passes through testing and review, and royalty payments of more than 10% on sales in those areas.<g> Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next